Does Rallies show Form 4 insider transactions for SGRY?

Yes. Rallies tracks SGRY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SGRY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SGRY. It does not provide personalized investment advice.

SGRY (Surgery Partners, Inc. Common Stock) Stock Analysis - Insider Trades

Surgery Partners, Inc. Common Stock (SGRY) is a publicly traded Healthcare sector company. As of May 20, 2026, SGRY trades at $13.52 with a market cap of $1.82B and a P/E ratio of -23.18. SGRY moved -1.46% today. Year to date, SGRY is -12.06%; over the trailing twelve months it is -41.85%. Its 52-week range spans $11.41 to $33.37. Analyst consensus is buy with an average price target of $19.75. Rallies surfaces SGRY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SGRY stock inside the company?

Recent SGRY insider activity includes Doherty David T sold 8.87K, Evans Jason Eric sold 20.40K, Burkhalter Danielle sold 3.47K, Brittenham Marissa sold 3.66K, and Baldock Jennifer sold 5.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SGRY Key Metrics

Key financial metrics for SGRY
Metric	Value
Price	$13.52
Market Cap	$1.82B
P/E Ratio	-23.18
EPS	$-0.59
Dividend Yield	0.00%
52-Week High	$33.37
52-Week Low	$11.41
Volume	764.58K
Avg Volume	0
Revenue (TTM)	$3.34B
Net Income	$97.10M
Gross Margin	0.00%

Recent SGRY Insider Trades

Doherty David T sold 8.87K (~$110.84K) on Mar 16, 2026.
Evans Jason Eric sold 20.40K (~$254.39K) on Mar 16, 2026.
Burkhalter Danielle sold 3.47K (~$44.51K) on Mar 13, 2026.
Brittenham Marissa sold 3.66K (~$45.86K) on Mar 13, 2026.
Baldock Jennifer sold 5.80K (~$76.36K) on Mar 12, 2026.

Latest SGRY News

Surgery Partners Q1 Revenue Climbs 4.5% to $810.9M, EBITDA $102.3M — May 5, 2026
Surgery Partners Forecasts 4% Q4 Growth, Authorizes $200M Buyback and M&A Spend — Mar 3, 2026
Surgery Partners Misses Q4 EPS, Sales Rise 2.4% to $885M — Mar 3, 2026
Surgery Partners Reports Q4 Revenue of $885M, EBITDA Margin Falls to 17.7% — Mar 3, 2026
Surgery Partners EPS Misses by 60%, Sales Guidance Cut to $3.35–$3.45 Billion — Mar 3, 2026

SGRY Analyst Consensus

11 analysts cover SGRY: 0 strong buy, 8 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.75.

Common questions about SGRY

Who is trading SGRY stock inside the company?: Recent SGRY insider activity includes Doherty David T sold 8.87K, Evans Jason Eric sold 20.40K, Burkhalter Danielle sold 3.47K, Brittenham Marissa sold 3.66K, and Baldock Jennifer sold 5.80K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SGRY?: Yes. Rallies tracks SGRY insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SGRY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SGRY. It does not provide personalized investment advice.